ciglitazone has been researched along with tretinoin in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.00) | 18.2507 |
2000's | 14 (70.00) | 29.6817 |
2010's | 5 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Gebicke-Haerter, PJ; Kakimura, J; Kitamura, Y; Matsuoka, Y; Nomura, Y; Taniguchi, T | 1 |
Bláha, L; Hofmanová, J; Kozubík, A; Minksová, K; Soucek, K; Stika, J; Vondrácek, J | 1 |
Frucht, H; Yang, WL | 1 |
Levine, L | 1 |
Breyer, B; Cheng, H; Feng, T; Haydon, RC; He, TC; Ishikawa, A; Jiang, W; Montag, A; Peabody, T; Simon, MA; Zhou, L | 1 |
Bernstein, SH; Phipps, RP; Ray, DM | 1 |
Allred, CD; Kilgore, MW | 1 |
Liu, QY; Nambi, P; Quinet, E | 1 |
Han, MK; Kim, BS; Kim, JS; Lee, SH; Lee, YR; Noh, EM; Park, J; Song, EK; Yu, HN | 1 |
Araki, H; Kanemura, N; Kojima, S; Matsushima-Nishiwaki, R; Moriwaki, H; Okuno, M; Shimizu, M; Tsurumi, H; Weinstein, IB; Yamazaki, K | 1 |
Lerch, R; Montessuit, C; Papageorgiou, I | 1 |
Grabacka, M; Laidler, P; Placha, W; Płonka, PM; Reiss, K; Urbanska, K | 1 |
Gawełko, J; Gonciarz, M; Konturek, SJ; Krawiec, A; Pawlik, WW; Pierzchalski, P | 1 |
Ferreri, AM; Guerra, F; Orlandi, M; Papi, A; Rocchi, P | 1 |
Ferreri, AM; Orlandi, M; Papi, A; Rocchi, P | 1 |
Ansari, S; Bright, JJ; Chearwae, W; Gupta, SK; Kanakasabai, S; Pestereva, E | 1 |
20 other study(ies) available for ciglitazone and tretinoin
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells.
Topics: Alitretinoin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cells, Cultured; Dinoprostone; Enzyme Induction; Gene Expression Regulation, Enzymologic; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Interferon-gamma; Lipopolysaccharides; Neuroglia; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Prostaglandin D2; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 1999 |
Inhibitors of arachidonic acid metabolism potentiate tumour necrosis factor-alpha-induced apoptosis in HL-60 cells.
Topics: Apoptosis; Arachidonic Acid; Caspase 3; Caspases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome c Group; Cytosol; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Indomethacin; Isoenzymes; Masoprocol; Membrane Proteins; Peroxisome Proliferators; Phospholipases A; Phospholipases A2; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin; Tumor Necrosis Factor-alpha | 2001 |
Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells.
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Fragmentation; Down-Regulation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Genes, cdc; HT29 Cells; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2001 |
Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors.
Topics: Alitretinoin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cell Line; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Indomethacin; Kinetics; Liver; Prostaglandin D2; Prostaglandins A; Pyrazoles; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Sulfonamides; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2001 |
Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Division; Chromans; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Osteosarcoma; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Neoplasm; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Tretinoin; Troglitazone; Tumor Cells, Cultured | 2002 |
Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Enzyme Activation; Humans; Immunohistochemistry; Immunologic Factors; In Situ Nick-End Labeling; Interleukin-6; Ligands; Membrane Potentials; Mitochondria; Multiple Myeloma; PPAR gamma; Prostaglandin D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Tretinoin | 2004 |
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
Topics: Alitretinoin; Anilides; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; HT29 Cells; Humans; Ligands; Lung Neoplasms; PPAR gamma; Prostaglandin D2; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Tretinoin | 2005 |
Adipocyte fatty acid-binding protein (aP2), a newly identified LXR target gene, is induced by LXR agonists in human THP-1 cells.
Topics: 5' Flanking Region; Adipocytes; Alitretinoin; Base Sequence; Binding Sites; Cell Differentiation; Cell Line; Dimerization; DNA-Binding Proteins; Drug Synergism; Fatty Acid-Binding Proteins; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; Macrophages; Molecular Sequence Data; Orphan Nuclear Receptors; PPAR gamma; Protein Binding; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Response Elements; Sequence Deletion; Sulfonamides; Thiazolidinediones; Tretinoin | 2007 |
Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells.
Topics: Cell Cycle; HL-60 Cells; Humans; PPAR gamma; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Thiazolidinediones; Tretinoin; Up-Regulation | 2007 |
Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management.
Topics: Caco-2 Cells; Colonic Neoplasms; Drug Synergism; Female; Growth Inhibitors; Humans; Male; Phosphorylation; PPAR gamma; Retinoid X Receptor alpha; Thiazolidinediones; Tretinoin | 2007 |
Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture.
Topics: Alitretinoin; AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Cytoskeleton; Glucose; Glucose Transporter Type 4; Insulin; Insulin Resistance; Male; Microtubules; Myocytes, Cardiac; Phenoxyacetates; PPAR gamma; Protein Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley; Retinoid X Receptors; Signal Transduction; Thiazolidinediones; Tretinoin | 2008 |
PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
Topics: Alitretinoin; Animals; Antigens, Differentiation; Antineoplastic Agents; beta Catenin; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Shape; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Melanocytes; Melanoma; Mice; Microphthalmia-Associated Transcription Factor; Monophenol Monooxygenase; Phenotype; PPAR gamma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Tretinoin; Up-Regulation | 2008 |
Molecular mechanism of protection against chemically and gamma-radiation induced apoptosis in human colon cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caco-2 Cells; Colonic Neoplasms; Gamma Rays; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Polymerase Chain Reaction; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazolidinediones; Tretinoin | 2008 |
Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Synergism; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasms; PPAR gamma; Retinoid X Receptors; Thiazolidinediones; Tretinoin | 2009 |
RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Synergism; HCT116 Cells; Humans; Ligands; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Pioglitazone; PPAR gamma; Response Elements; Retinoid X Receptor gamma; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcriptional Activation; Tretinoin | 2010 |
PPARγ agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes.
Topics: Animals; Antigens; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Epidermal Growth Factor; Fibroblast Growth Factor 2; Gene Expression; Glial Fibrillary Acidic Protein; Intermediate Filament Proteins; Mice; Nerve Tissue Proteins; Nestin; Neural Stem Cells; Oligodendroglia; PPAR gamma; Prostaglandin D2; Proteoglycans; Thiazolidinediones; Tretinoin; Tubulin | 2012 |